• Traverse
    • Kilimanjaro 2023
    • Timmerman Traverse for LSC 2022
    • Everest Base Camp trek 2022
    • Timmerman Traverse for LSC 2021
    • Kilimanjaro 2019
    • Mt. Everest Summit 2018
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Your Edge In Biotech.
  • Traverse
    • Kilimanjaro 2023
    • Timmerman Traverse for LSC 2022
    • Everest Base Camp trek 2022
    • Timmerman Traverse for LSC 2021
    • Kilimanjaro 2019
    • Mt. Everest Summit 2018
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
20
Feb
2015

Five Things to Watch at Next Week’s Big Genomics Show

/
Luke Timmerman
/
1
/
All, Cancer, Diagnostics, FDA, Genomics, Science
20 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Feb
2015

Global Blood Zeroes in on Sickle Cell, a Potentially Big, and Touchy, Opportunity

/
Luke Timmerman
/
1
/
All, Drugs, FDA
19 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Feb
2015

Frazier, Versant Find an AFib Drug To Bet on at Laguna

/
Luke Timmerman
/
0
/
All, Drugs, Finance, Venture Capital
17 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Feb
2015

How’s It Going at the Biotech Journalism Startup? Much Better Than Expected

/
Luke Timmerman
/
2
/
All, Diagnostics, Drugs, Genomics
13 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Feb
2015

Video: Alnylam’s John Maraganore and Canaan’s Julie Papanek at BIO CEO

/
Luke Timmerman
/
0
/
All, Devices, Drugs, Venture Capital
12 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Feb
2015

Intelligent MDx, Maker of Molecular Diagnostics That Raised $40M, Shuts Down

/
Luke Timmerman
/
0
/
All, Diagnostics, Science
11 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Feb
2015

FAQs About the Timmerman Report

/
Luke Timmerman
/
0
/
All, Cancer, Devices, Diagnostics, Drugs
11 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Feb
2015

Cellular Dynamics Tracks Down ‘Superdonors’ for Cell Therapy

/
Luke Timmerman
/
0
/
All, Science, Strategy
09 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Feb
2015

Q&A: Affymetrix Founder Stephen Fodor Resurfaces at Cellular Research

/
Luke Timmerman
/
1
/
All, Cancer, Devices, Genomics, Strategy
06 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Feb
2015

Former Dendreon CEO Lures Ex-Amgen Scientists to Immunotherapy Startup

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
05 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Feb
2015

Seattle Genetics Commercial Boss Leaves for President Gig at Bristol-Myers

/
Luke Timmerman
/
1
/
All, Cancer, Drugs, Strategy
04 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Feb
2015

Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down

/
Luke Timmerman
/
11
/
All, Drugs, Science, Strategy
04 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

The Merck Exodus: Where Are the Talented People Going?

/
Luke Timmerman
/
3
/
All, Drugs, FDA, Finance, Science, Strategy
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

Implications of the Biotech Boom on the Business and Science of R&D

/
Luke Timmerman
/
3
/
All, Drugs, Finance
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

Welcome to the Timmerman Report

/
Luke Timmerman
/
8
/
All
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 63 64 65

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

The Long Run Podcast

The Long Run Podcast

Sponsored By

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2023, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder